vonoprazan + clarithromycin + amoxicillin + bismuth potassium citrate

A four-drug oral combination consisting of **vonoprazan**, **clarithromycin**, **amoxicillin**, and **bismuth potassium citrate** designed for the eradication of *Helicobacter pylori* infection. Vonoprazan is a potassium-competitive acid blocker (P-CAB) that provides rapid and sustained gastric acid suppression. Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis. Amoxicillin is a beta-lactam antibiotic that interferes with bacterial cell wall synthesis. Bismuth potassium citrate acts as a mucosal protective agent and has local antimicrobial activity, particularly useful for managing antibiotic resistance. This quadruple therapy is used especially as first-line treatment or in areas with high rates of antibiotic resistance for *H. pylori* eradication, offering high eradication rates and favorable tolerability[3][2][4].

Brand names

Takecab

Other names

vonoprazan-based bismuth quadruple therapyVBQT